Release
2025/02/26
OSAKA, Japan, February 26, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter “SHIONOGI”) announces that it will implement the following corporate reorganization, new establishment and personnel reassignment, effective April 1, 2025.
1.Purpose of corporate reorganization and new establishment
I. R&D Supervisory Unit
- A Venture Alliance Management Office will be established under the R&D Supervisory Unit to engage in new, non-DX/IT-related businesses, venture capital investments, etc.
II. Healthcare Business Supervisory Unit
- The Government Affairs Department will be transferred from the Healthcare Business Supervisory Unit to the Integrated Disease Care Division.
- The Partnership Promotion Office will be dissolved and its functions integrated into the Government Affairs Department to clarify the role of negotiations with external institutions.
- A Digital Marketing Office will be established under the Integrated Disease Care Division to promote more systematic use of digital technology in formulating and implementing marketing strategies.
- The New Business Promotion Department will be dissolved and its functions transferred to the DX New Business Promotion Office under the DX Promotion Division and the Venture Alliance Management Office under the R&D Supervisory Unit.
III. Corporate Supervisory Unit
- The Administration Division will be renamed the Sustainability Management Division to strengthen SHIONOGI’s management base for sustainable growth.
- To further strengthen dialogue and collaboration with internal and external stakeholders, the Corporate Social Responsibility Department will be dissolved and integrated into the Corporate Communications Department. The Office for Children’s Bright Future will be transferred to the Corporate Communications Department.
- The General Administration Department will be renamed the Corporate Governance Department to clarify the department responsible for corporate governance functions on a global basis.
- A Global HR Strategy Office will be established to engage in the globalization of human resources and global HR functions to globalize corporate functions. The Human Capital Strategy Office, the Career Development Office and the Business Administration Office will be dissolved.
- The functions of the Legal Affairs and Compliance Departments will be merged to form the Legal Affairs and Compliance Department.
- The promotional compliance framework will be strengthened, including compliance with the Guidelines for Provision of Sales Information.
- A DX New Business Promotion Office will be established under the DX Promotion Division to engage in DX/IT-related new businesses.
2.Personnel Reassignments (Effective; April 1, 2025)
Name |
New Position |
Current Position |
R&D Supervisory Unit |
||
John Keller |
Senior Vice President, R&D Supervisory Unit and Pharmaceutical Technology Research Division |
Senior Vice President, R&D Supervisory Unit |
Hirohide Nambu |
Vice President, Business Development Department |
Vice President, R&D Supervisory Unit Office and Diagnostic Drug Office |
Kenji Yamawaki |
Vice President, Intellectual Property Department |
Vice President, Laboratory for Medicinal Chemistry Research |
Takafumi Sato |
Vice President, R&D Supervisory Unit Office |
Vice President, Laboratory for Drug Discovery and Disease Research |
Gaku Sakaguchi |
Vice President, Diagnostic Drug Office |
Vice President, New Business Promotion Department |
Soichi Shiono |
Vice President, Venture Alliance Management |
Business Development Department |
Drug Discovery Research Division |
||
Toshiyuki Asaki |
Senior Vice President, Drug Discovery Research Division |
President, Shionogi Techno Advance Research Co., Ltd. |
Yuki Tachibana |
Vice President, Medicinal Chemistry Research |
Vice President, Business Development Department |
Erika Kasai |
Vice President, Drug Discovery and Disease Research |
Drug Discovery Research Division |
Kumio Masuda |
Vice President, Drug Discovery and Development |
Vice President, Office for Children’s Bright Future |
Jun Yoshimoto |
President, Shionogi Techno Advance Research Co., Ltd. |
Senior Vice President, Drug Discovery Research Division and Laboratory for Drug Discovery and Development |
Pharmaceutical Technology Research Division |
||
Yuko Yamamoto |
Vice President, Formulation R&D Research Department |
Shionogi Pharma Co., Ltd |
Chie Kishimoto |
Vice President, Analysis and Evaluation Department |
Vice President, Regulatory Affairs Department |
Name |
New Position |
Current Position |
Drug Development and Regulatory Science Division |
||
Masako Kaneto |
Vice President, Regulatory Affairs Department |
Vice President, Pharmacovigilance Department |
Yuka Niimi |
Vice President, Pharmacovigilance Department |
Vice President, Sustainability Management Department |
Healthcare Business Supervisory Unit |
||
Toshiyuki Aoi |
Vice President, Drug Information Center |
Vice President, Promotion Department - Region 2 |
Chin-Min Lin |
President, Taiwan Shionogi & Co., Ltd |
Taiwan Shionogi & Co., Ltd |
Masahiro Fujita |
President, Beijing Shionogi Pharmaceutical Technology Limited |
Healthcare Business Supervisory Unit Office |
Yuuko Nakagawa |
President, Shionogi Healthcare Co., Ltd |
Join |
Pharmaceutical Commercial Division |
||
Naoto Furuta |
Senior Vice President, Healthcare Business Supervisory Unit |
Vice President, Distribution Management Department |
Kazuya Ishida |
Vice President, Promotion Department - Region 2 |
Vice President, Promotion Department - Region 4 |
Minoru Motokane |
Vice President, Promotion Department - Region 3 |
Vice President, Sales Promotion Department |
Masashi Katsumata |
Vice President, Promotion Department - Region 4 |
Vice President, Promotion Department - Region 3 |
Atsushi Matsuuchi |
Vice President, Promotion Department - Region 5 |
Promotion Department - Region 1 |
Souichirou Mitsutake |
Vice President, Distribution Management Department |
Vice President, Promotion Department - Region 5 |
Atsushi Sano |
Vice President, Sales Promotion Department |
Promotion Department - Region 2 |
Integrated Disease Care Division |
||
Satoru Yoshimoto |
Senior Vice President, Integrated Disease Care Division |
President, Shionogi Healthcare Co., Ltd |
Keiko Tone |
Vice President, Digital Marketing office |
SHIONOGI BV |
Supply Supervisory Unit |
||
Akira Kato |
Senior Vice President, Supply Supervisory Unit |
President, Shionogi Pharma Co., Ltd |
Yasunori Aoyama |
Vice President, Global Supply Chain Strategy Department |
Senior Vice President, Pharmaceutical Technology Research Division |
Yasuyoshi Iso |
President, Shionogi Pharma Co., Ltd |
Senior Vice President, Drug Discovery Research Division |
Corporate Supervisory Unit |
||
Kazuhiro Hatanaka |
Senior Vice President, Corporate Supervisory Unit |
Senior Vice President, Corporate Supervisory Unit and Corporate Strategy Division |
Name |
New Position |
Current Position |
Corporate Strategy Division |
||
Masako Kudo |
Senior Vice President, Corporate Strategy Division |
Vice President, Finance & Accounting Department |
Takuji Fujiwara |
Vice President, Finance & Accounting Department |
Vice President, Business Administration Office |
Takaho Kawamoto |
Vice President, Human Resources Department |
Vice President, Human Resources Department and Human Capital Strategy Office |
Yohei Seki |
Vice President, Global HR Strategy Office |
Vice President, Career Development Office |
Sustainability Management Division |
||
Masashi Deguchi |
Senior Vice President, Sustainability Management Division |
Senior Vice President, DX Promotion Division |
Izumi Ishikawa |
Vice President, Office for Children’s Bright Future and President of Yui Connection Co., Ltd |
Vice President, Analysis and Evaluation Laboratory |
Kazuyo Hirao |
Vice President, Corporate Governance Department |
Vice President, General Administration Department |
Hiroyuki Tanaka |
Vice President, Sustainability promotion Department and President of Shionogi Smile Heart Co., Ltd. |
Vice President, Corporate Social Responsibility Department and President of Shionogi Smile Heart Co., Ltd. |
DX Promotion Division |
||
Yosuke Miharu |
Senior Vice President, DX Promotion Division, DX New Business Promotion Office and President of Stream I Co., Ltd. |
Senior Vice President, Integrated Disease Care Division and President of Stream I Co., Ltd. |
Corporate Quality Assurance and Ethics & Compliance Management Division |
||
Aki Ikebata
|
Vice President, Legal/Compliance Department |
Vice President, Legal Department |
For Further Information, Contact:
SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html